A compare study on Human recombinant Thrombopoietin (TPIAO) promote platelet recovery in haploidentical Hematopoietic Stem Cell Transplantation recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001774

Enrollment

Unknown

Registered

2011-12-03

Start date

2010-11-16

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant hematological disease, Hematopoietic Stem Cell Transplantation

Interventions

A:TPIAO

B:No treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18-60 years old; 2. malignant hematological disease,Hematopoietic Stem Cell Transplantation; 3. platelet above 100*10^9/L before conditioning; 4. BUCY+ATG regimen for conditioning; 5. have normal liver and renal function, or GPT/GOT <1.5 normal uplimit.

Exclusion criteria

Exclusion criteria: not fit for any one of the five inclusion criteria

Design outcomes

Primary

Measure	Time frame
incidence of platelet engraftment;	—

Countries

China

Contacts

Public ContactXiaojun Huang

xjhrm@medmail.com.cn+86 13701389625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026